Descripción del proyecto
Investigar los mecanismos de comorbilidad de la depresión y las enfermedades cardiovasculares
La depresión está muy asociada con las enfermedades cardiovasculares y aumenta considerablemente el riesgo de desarrollar una enfermedad cardiovascular, episodios agudos y mortalidad, especialmente en las mujeres. Por ello, representa un problema social y económico que afecta a la vida del paciente y provoca un aumento de los costes de la sanidad. Sin embargo, siguen sin conocerse los mecanismos y la progresión de la enfermedad. El proyecto TO_AITION, financiado con fondos europeos, trabaja sobre la hipótesis de que la desregulación metabólico-inmunitaria debida a factores medioambientales, genéticos y del estilo de vida afecta a los mecanismos inmunitarios, lo que conduce a la depresión asociada con las enfermedades cardiovasculares. El proyecto realizará una investigación clínica y preclínica básica a través de la aplicación de estrategias basadas en datos para detectar y describir los mecanismos metabólico-inmunitarios responsables de la comorbilidad de la depresión y las enfermedades cardiovasculares, con el objetivo de mejorar el diagnóstico y la gestión de la enfermedad.
Objetivo
Depression is a common and serious comorbidity of cardiovascular disease (CVD) affecting one in three patients, among which women earlier and more frequently. Depression increases the risk for CVD development, acute events and mortality by >2 fold, independently of traditional risk factors, and constitutes an enormous socioeconomic burden in terms of morbidity, mortality and healthcare costs. Still, the patients at risk, disease trajectories and causative mechanisms involved remain unknown.
TO_AITION addresses the hypothesis that immune-metabolic dysregulation, occurring as a result of genetic, lifestyle and environmental risk factors ‘training’ innate immunity, drives low grade systemic inflammation leading to the development of CVD-depression comorbidity.
It integrates basic (cell models, immune-metabolic mechanisms, myeloid cell reprogramming), preclinical (animal models, CRISPR genome editing) and clinical (longitudinal cohorts with comprehensive existing data) research, in order to characterise immune-metabolic mechanisms driving CVD-depression comorbidity. Both hypothesis and data-driven strategies will be employed to address causality, focusing on genetic, epigenetic, transcriptional, metabolic and other disturbances leading to the development of comorbidity. Drug-drug interactions and their effects on causative mechanisms and disease trajectories will also be determined. Pathways identified will be evaluated in cell-based and animal models to prove their causal role and obtain mechanistic insight. Finally, new risk models will be developed, and relevant regulatory, cost-effectiveness and feasibility issues addressed. Effective patient-oriented awareness actions, dissemination, exploitation and management activities are also provisioned.
TO_AITION will therefore rationally change our current understanding of the causative mechanisms driving CVD-depression comorbidity, unravelling patients’ complexity and improving their diagnosis, monitoring and management.
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2019-Two-Stage-RTD
Régimen de financiación
RIA - Research and Innovation actionCoordinador
115 27 Athina
Grecia